SAN FRANCISCO, CA / ACCESSWIRE / October 25, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that on December 7, 2023, the company will present results from its pivotal Phase 3 OnTarget study of Napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the San Antonio Breast Cancer Symposium (SABCS). Napo expects to announce top line results of the trial by the Thanksgiving holiday.
SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Pharmaceuticals, the company's wholly owned subsidiary, today announced the completion of a third-party, investigator-initiated preclinical enterocyte (intestinal cell) in vitro study to evaluate the effects of crofelemer,Napo Pharmaceuticals' plant-based prescription drug, on certain genetic defects that result in specific forms of congenital diarrheal disorders. Jaguar Health believes that these study results will support certain requests received from the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA) in response to the Orphan Drug Designation (ODD) application Napo Pharmaceuticals filed with the FDA for crofelemer for congenital diarrheal disorders (CDD) in infants and children.
SAN FRANCISCO, CA / ACCESSWIRE / October 7, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) provided updates today regarding ongoing research and development related to the company's crofelemer drug product candidates, and also announced that Dragon SPAC S.p.A. and Napo EU S.p.A., the company's Italian subsidiary, have submitted the required notification in order to have the impending merger of Dragon SPAC and Napo EU approved as required by Italy's laws.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Napo Pharmaceuticals, Inc. (Napo), the wholly owned US subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), today announced the signing of a license agreement with Napo's Italian subsidiary, Napo EU S.p.A., to study, develop, and commercialize Napo's plant-based crofelemer and lechlemer drug product candidates in the European Union and in specified non-EU countries in Europe for specific indications. Per the terms of the license agreement, Napo will receive payment of up to US$10 million (to be paid in two installments) as the initial license fee and is eligible to receive additional payments related to milestones, royalties, and product transfers.
Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer
SAN FRANCISCO, CA (February 28, 2017) — Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally used in rainforest areas, announces today that it has signed an agreement with Alamo Pharma Services, Inc. for the establishment and management of a national sales team for Mytesi™ (formerly known as Fulyzaq). Mytesi™, launched by Napo in October 2016, is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.